Celgene’s Abraxane combo flops in phase 3 cancer trials
March 14, 2019Research and Development Abraxane, Celgene, clinical trials, pharma, trials
Celgene’s Abraxane, in combination gemcitabine, has failed to meet its primary endpoint in a pivotal Phase 3 trial of patients …
New class of drugs offer alternative to statins
March 14, 2019Research and Development cholesterol, health, imperial college london, research, statins
A new class of cholesterol lowering drugs may help patients who are unable to take statins, according to a study …
Sandoz CEO Richard Francis to step down
March 14, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Novartis, Sandoz, appointment, pharma
Richard Francis is set to step down his role as Chief Executive of Novartis’ generics arm Sandoz after five years’ …
Califonia court rules J&J must pay woman with mesothelioma $29 million
March 14, 2019Medical Communications, Sales and Marketing
A California jury has ordered American healthcare conglomerate Johnson & Johnson to pay more than $29 million to a woman …
National Cancer Institute Director Ned Sharpless to become interim FDA Commissioner
March 13, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Ned Sharpless, Scott Gottlieb, appointment, pharma
Following the surprise resignation of current FDA Commissioner Dr Scott Gottlieb a week earlier, Dr Norman ‘Ned’ Sharpless, Director of …
Janssen’s ulcerative colitis treatment shows positive results in phase 3 trials
March 13, 2019Manufacturing and Production, Research and Development Jansenn, Stelara, phase 3 trials, ulcerative colitis
Janssen’s ulcerative colitis treatment, Stelara (ustekinumab subcutaneous) has shown positive results as maintenance therapy in phase 3 trials. The study …
Lilly’s Cyramza hits Phase 3 endpoint in first-line metastatic lung cancer treatment
March 13, 2019Research and Development Cancer, Eli Lilly, cyramza, lung cancer, pharma
Eli Lilly’s vascular endothelial growth factor (VEGF) Receptor 2 antagonist Cyramza (ramucirumab) has succeeded in hitting its primary endpoint at …
Healthcare industry could take up to five years to stabilise after no-deal Brexit
March 13, 2019Manufacturing and Production, Medical Communications, Research and Development GlobalData, analysis, brexit, no-deal Brexit, surveys
The healthcare industry could take up to five years to stabilise in the event of a no-deal Brexit, according to …
FDA approve valsartan generic after shortages of supply
March 13, 2019Manufacturing and Production, Research and Development FDA, blood pressure drugs, cardiovascular, generic, valsartan
The FDA has approved a new generic version of blood pressure drug valsartan. The approval comes amid shortages in supply …
Innate Pharma hires Jennifer Butlers to lead commercialisation of leukaemia drug Lumoxiti
March 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
French company Innate Pharma have announced the appointment of Jennifer Butler to the position of Executive Vice President and General …
FDA expands Dupixent indication to include moderate-to-severe atopic dermatitis in adolescent patients
March 12, 2019Manufacturing and Production, Sales and Marketing Dupixent, Regeneron, Sanofi, pharma
Partners Sanofi and Regeneron have both revealed that their jointly developed drug Dupixent (dupilumab) has been authorised by the FDA …
Dr Reddy’s demand more than $70 million from Indivior over generic Suboxone Film
March 12, 2019Manufacturing and Production Dr Reddy's, Suboxone Film, court, indivior, opioid addiction
Indian firm Dr Reddy’s is seeking at least $70 million from British firm Indivior Plc as compensation for lost sales …
NICE recommends Janssen’s Darzalex myeloma combo
March 12, 2019Manufacturing and Production Janssen, NICE, Velcade, darzalex, myeloma
Britain’s cost effectiveness body NICE have recommended Janssen Pharmaceutical’s Darzalex in combination with Velcade and dexamethasone (DVd), for use within …
FDA approves Pfizer’s Herceptin biosimilar Trazimera
March 12, 2019Manufacturing and Production, Sales and Marketing Humira, Pfizer, Trazimera, biosimilar, pharma
Patients in the US will now be able to access another biosimilar version of Herceptin (trastuzumab) with the FDA approval …
Scottish Medicines Consortium rejects Novartis’ CAR T therapy Kymriah
March 12, 2019Manufacturing and Production Kymriah, NICE, Novartis, SMC, Scotland, UK
Scotland’s cost effectiveness body has refused to fund Novartis’ CAR T therapy Kymriah for adult patients with lymphoma. The Scottish …
PV futures: Pharmacovigilance as a solution to the challenges of tomorrow
March 11, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing drug safety, feature, pharma, pharmacovigilance
Louis Goss asks what the future might hold for the safety of pharmaceuticals and looks into why crucial pharmacovigilance practices …
FDA approves first diagnostic tool to target triple-negative breast cancer patients
March 11, 2019Sales and Marketing Cancer, Roche, Ventana, breast cancer, pharma
Roche’s Ventana PD-L1 Assay has become the first FDA-approved companion diagnostic for the identification of patients with triple-negative breast cancer …
AMAG Pharmaceuticals’ shares fall 21% after failed Makena trial
March 11, 2019Sales and Marketing AMAG Pharmaceuticals, Makena, PROLONG, birth, trials
AMAG Pharmaceuticals’ Makena (hydroxyprogesterone caproate) has failed to meet its co-primary endpoints in a trial of patients with a history …
FDA advisory panel recommends Sanofi’s dengue vaccine in children, but rejects its use in adults
March 11, 2019Sales and Marketing FDA, Sanofi, US, Vaccine, dengue, dengvaxia, pharma
Dengvaxia, Sanofi’s vaccine for dengue fever, has been burdened with further negative scrutiny after the FDA’s vaccine advisory panel passed …
US DoJ launch investigation into Acadia Pharmaceuticals
March 11, 2019Sales and Marketing False Claims Act, SEC, acadia, antipsychotics, kickbacks
The US Department of Justice has launched an investigation into the sales and marketing practices of San Diego firm Acadia …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
